1. [Neurology].
- Author
-
Chopard I, Benninger D, Demonet JF, Du Pasquier R, Hirt L, Kuntzer T, Michel P, Nater B, Novy J, Rossetti A, Rouaud O, Ryvlin P, Schluep M, and Theaudin M
- Subjects
- Humans, Prealbumin therapeutic use, Rituximab therapeutic use, Amyloid Neuropathies, Familial drug therapy, Myasthenia Gravis drug therapy, Neurology trends
- Abstract
Ocrelizumab (Ocrevus), an anti-CD20 monoclonal antibody, has been approved for the treatment of multiple sclerosis. Eculizumab (Soliris) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis. A form of gene therapy, patisiran, has shown positive results in transthyretin familial amyloidosis. In the treatment of headaches, particularly migraines, non-pharmacological approaches have shown some interesting results. The criteria for Lewy body dementia have been revised. Generic use of lamotrigine does not result in recrudescence of epileptic seizures or adverse effects., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
- Published
- 2018